FDA
-
-
-
-
-
-
-
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
-
-
-
-
-
-
-
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
-
-
-
-
-
-
-
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-
-
-
-
-
-
-
-
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
-
-
-
-
-
-
-
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
-
-
-
-
-
-
-
G1 Therapeutics (GTHX) Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
-
-
-
-
-
-
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
251,613 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All